Proto Labs Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Proto Labs Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $344.49M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $298.06M | Feb 23, 2018 |
| FY2017 | Dec 31, 2015 | $264.11M | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $209.58M | Feb 22, 2017 |
| FY2015 | Dec 31, 2013 | $163.11M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $125.99M | Feb 27, 2015 |
| FY2013 | Dec 31, 2011 | $98.94M | Feb 28, 2014 |
| FY2012 | Dec 31, 2010 | $64.92M | Mar 22, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.14M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $223.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $221.99M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $215.47M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $222.69M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $217.83M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $235.29M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $238.68M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $193.84M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $166.94M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.24M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $16.59M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $17.22M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($103.46M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $33.37M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $50.87M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $63.66M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $76.59M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $51.78M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $42.71M | Feb 22, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.11M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $19.91M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $28.17M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($97.98M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $40.34M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $59.84M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $79.86M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $88.90M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $72.23M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $61.77M | Feb 22, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.81M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $41.30M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $40.14M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $38.22M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $44.24M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $36.94M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $32.69M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $28.74M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $23.56M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $22.39M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.50M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $77.83M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $73.27M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $62.08M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $55.24M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $106.97M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $116.05M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $122.93M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $81.75M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $77.50M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.84M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $9.17M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $28.12M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $21.69M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $34.21M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $47.01M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $62.23M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $87.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $32.64M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $33.62M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $763.42M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $743.51M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $772.35M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $802.17M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $928.58M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $744.20M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $673.67M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $618.99M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $518.74M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $414.24M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.48M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $73.36M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $77.06M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $104.52M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $100.09M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $99.85M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $87.88M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $77.49M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $57.52M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $34.41M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $673.93M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $670.15M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $695.30M | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $697.65M | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $828.49M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $644.36M | Feb 16, 2024 |
| FY2022 | Dec 31, 2019 | $585.79M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $541.50M | Feb 18, 2022 |
| FY2020 | Dec 31, 2017 | $461.22M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $379.83M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $273.99M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $273.99M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $273.99M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $273.99M | Feb 16, 2024 |
| FY2023 | Dec 31, 2021 | $400.61M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $128.75M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $128.75M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $128.75M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $128.50M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $28.92M | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.76M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $244.41M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $256.40M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $258.24M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $376.73M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $362.90M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $324.72M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $291.46M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $224.70M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $176.70M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.83M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $89.07M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $83.79M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $56.56M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $65.93M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $127.60M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $125.23M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $85.05M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $36.71M | Feb 26, 2020 |
| FY2019 | Dec 31, 2016 | $68.80M | Feb 26, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $363.0K | Feb 28, 2014 |
| FY2012 | Dec 31, 2011 | $629.0K | Mar 22, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 22, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 22, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.63M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 24.23M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 25.72M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 26.89M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 27.47M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 26.78M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 26.79M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 26.98M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 26.83M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 26.50M | Feb 23, 2018 |